Why PRP evidence changes with the sore body part

Does PRP work the same for every sore spot?

No, and that's the honest short answer. Some knee arthritis studies found less soreness and easier movement after PRP.

Other studies found that PRP didn't help more than the comparison care. Research on the hip, shoulder, and other joints gives fewer clear answers.

The word tendon means firm tissue connecting muscle and bone. Researchers checked soreness and how well people could use the sore part.

The results changed with the injured tendon and type of harm. Your provider can't choose wisely before finding the painful tissue.

What can help before a procedure comes up?

Spreading out chores and doing the right exercises may ease strain. If needed, losing some weight can reduce the load on a knee.

You might use a cane or brace to put less weight there. These steps may help you move and show what still bothers you.

If you visit QC Kinetix, regenerative treatments means blood-based care given there without surgery. A medical provider is the staff member checking the sore area and talking through your choices.

When might another kind of care make more sense?

Badly worn joints may make surgery worth discussing. A broken bone, sudden tear, or hot swollen joint needs quick care first.

PRP can't replace an exam that finds the cause. It also won't promise to return worn tissue to normal.

Ask what other care remains if PRP doesn't help. You'll want that answer before spending your money.

Sources

1. In the RESTORE trial - the largest placebo-controlled PRP trial in knee osteoarthritis - 288 adults aged 50+ with symptomatic Kellgren-Lawrence grade 2-3 medial knee OA received three weekly intra-articular injections of leukocyte-poor PRP from a commercial system or saline placebo. At 12 months the mean change in knee pain was -2.1 points with PRP versus -1.8 with saline (difference -0.4; 95% CI -0.9 to 0.2; P=.17) against a minimum clinically important difference of 1.8, and the change in medial tibial cartilage volume was -1.4% versus -1.2% (difference -0.2%; 95% CI -1.9% to 1.5%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no significant between-group difference. The authors concluded the findings do not support use of PRP for knee OA.

   Bennell KL, Paterson KL, Metcalf BR, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

2. The AAOS third-edition clinical practice guideline for non-arthroplasty management of knee osteoarthritis contains 29 recommendations, and the work group explicitly identified intra-articular corticosteroid, hyaluronic acid AND platelet-rich plasma as areas needing better research - including osteoarthritis characterisation, severity stratification, clinically relevant outcomes with controls for bias, and cost-effectiveness analysis. PRP is presented as an open research question in this guideline, not as a settled treatment.

   Brophy RH, Fillingham YA — AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition. Journal of the American Academy of Orthopaedic Surgeons, 2022. DOI: 10.5435/JAAOS-D-21-01233.

3. A systematic review of 105 clinical PRP studies in orthopaedics published 2006-2016 found that only 11 (10%) described the preparation protocol clearly enough for another investigator to repeat it, and only 17 (16%) reported any quantitative metric of the final PRP composition. The authors concluded that the current reporting of PRP preparation and composition does not allow the PRP products actually delivered to patients to be compared between studies.

   Chahla J, Cinque ME, Piuzzi NS, et al. — A Call for Standardization in Platelet-Rich Plasma Preparation Protocols and Composition Reporting: A Systematic Review of the Clinical Orthopaedic Literature. Journal of Bone and Joint Surgery (American), 2017. DOI: 10.2106/JBJS.16.01374.

4. A systematic review of 132 Level I/II PRP studies across all medical specialties, covering 28 different conditions, found inconsistent reporting of PRP composition in every field of medicine. Musculoskeletal indications - knee osteoarthritis and tendinopathy above all - accounted for the majority of high-level studies. Sixty-one percent of the studies reported PRP as favourable over the control treatment, with no difference in that proportion between musculoskeletal and non-musculoskeletal specialties.

   Nazaroff J, Oyadomari S, Brown N, et al. — Reporting in clinical studies on platelet-rich plasma therapy among all medical specialties: A systematic review of Level I and II studies. PLOS ONE, 2021. DOI: 10.1371/journal.pone.0250007.

5. A meta-analysis of 15 studies in plantar fasciitis found PRP superior to corticosteroid on AOFAS at 6 and 12 months (P=.009 both) and on VAS at 3, 6 and 12 months, with no advantage in the first month. The authors added the caveat that nine of the fifteen studies had a high risk of bias and that 'different protocols for PRP preparation reduce the internal and external validity of these findings' - the preparation problem stated as an explicit limit on the conclusion.

   Hohmann E, Tetsworth K, Glatt V — Platelet-Rich Plasma Versus Corticosteroids for the Treatment of Plantar Fasciitis: A Systematic Review and Meta-analysis. American Journal of Sports Medicine, 2021. DOI: 10.1177/0363546520937293.

6. The Cochrane review of platelet-rich therapies for musculoskeletal soft-tissue injuries concluded there is currently insufficient evidence to support the use of platelet-rich therapy for treating musculoskeletal soft tissue injuries, overall and for individual conditions - including pooled data from six trials of PRP applied during rotator cuff repair surgery, which showed no statistically or clinically significant long-term functional difference. The review ended with an explicit call for standardisation of PRP preparation methods.

   Moraes VY, Lenza M, Tamaoki MJ, et al. — Platelet-rich therapies for musculoskeletal soft tissue injuries. Cochrane Database of Systematic Reviews, 2014. DOI: 10.1002/14651858.CD010071.pub3.

7. A PROSPERO-registered systematic review of PRP for low back pain graded the quality of the supporting evidence as LEVEL II, reporting positive results in almost all included studies, few adverse events, and low risk of bias in 11 of 13 papers. Applying an adapted MIBO reporting checklist to those studies produced only a 72.7% compliance rate, so even the favourable spine literature is incompletely reported.

   Machado ES, Soares FP, Vianna de Abreu E, et al. — Systematic Review of Platelet-Rich Plasma for Low Back Pain. Biomedicines, 2023. DOI: 10.3390/biomedicines11092404.

8. The ESSKA-ICRS consensus applied the RAND/UCLA appropriateness method to 216 clinical scenarios for intra-articular PRP in knee OA. Only 84 scenarios (38.9%) were rated appropriate, 9 (4.2%) inappropriate and 123 (56.9%) uncertain. PRP was judged appropriate in patients aged 80 or under with KL grade 0-III osteoarthritis AFTER failed conservative non-injective or injective treatment; it was NOT considered appropriate as a first treatment, nor in KL grade IV (bone-on-bone) osteoarthritis, where 91.7% and 87.5% of scenarios respectively were uncertain.

   Kon E, de Girolamo L, Laver L, et al. — Platelet-rich plasma injections for the management of knee osteoarthritis: The ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12320.

9. The American Academy of Physical Medicine and Rehabilitation convened a technical expert panel that ran a structured literature review (2023, updated through June 2025) and a modified Delphi process, and issued five evidence-based clinical recommendations plus 11 consensus-based best practices for PRP in knee osteoarthritis. The statement is explicit that orthobiologic therapies 'remain an evolving area of practice' and that robust, dose-dependent randomized controlled trials are still needed to establish PRP's clinical effects.

   Borg-Stein J, Jayaram P, Colorado BS, et al. — AAPM&R guidance statement on platelet rich plasma for knee osteoarthritis. PM&R, 2026. DOI: 10.1002/pmrj.70144.

10. The devices used to spin PRP at the point of care are cleared by FDA as clinical centrifuges, product code JQC, a Class I device under 21 CFR 862.2050 - for example the Biomet GPS Platelet Separation Kit (K030555, cleared 2003) and the Harvest SmartPrep2 / SmartPrep Platelet Concentration System (K103340, cleared 2010). That clearance covers the equipment that separates blood. It is not an FDA approval of platelet-rich plasma as a treatment for osteoarthritis, tendinopathy or any other orthopedic condition, and copy must never blur the two.

    U.S. Food and Drug Administration (Center for Devices and Radiological Health) — 510(k) Premarket Notification database and Product Classification: JQC, Centrifuges (Micro, Ultra, Refrigerated) For Clinical Use, 21 CFR 862.2050. FDA accessdata (CDRH device databases), 2003.